Patient and Provider Initiated Survivorship Care Planning
NCT02405819 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41
Last updated 2016-04-21
Summary
Objective: to describe and compare the implementation of two cancer survivorship care tools: (1) 'My Care Plan': a patient-initiated tool and (2) 'Survivorship Care Plan Builder': a provider-initiated tool. The results of this study will be used to (1) provide an initial assessment of the two survivorship care planning tools and (2) inform the design and conduct of a larger study.
Conditions
Interventions
- OTHER
-
'My Care Plan'
'My Care Plan' is a patient-initiated survivorship care planning tool.
- OTHER
-
'Survivorship Care Plan Builder'
'Survivorship Care Plan Builder' is a provider-initiated survivorship care planning tool.
Sponsors & Collaborators
-
Genentech, Inc.
collaborator INDUSTRY -
WellPoint, Inc.
collaborator INDUSTRY -
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
lead OTHER
Principal Investigators
-
Katherine C Smith, Ph.D. · Johns Hopkins Bloomberg School of Public Health
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 21 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-02-28
- Primary Completion
- 2016-02-29
- Completion
- 2016-02-29
Countries
- United States
Study Locations
More Related Trials
-
An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy
NCT00191646 ·Status: COMPLETED ·Phase: PHASE3
-
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
NCT00090610 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
NCT05082025 ·Status: TERMINATED ·Phase: PHASE2
-
Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and Their Caregivers
NCT02412124 ·Status: TERMINATED ·Phase: NA
-
Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers
NCT00231855 ·Status: COMPLETED ·Phase: PHASE2
-
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
NCT01372787 ·Status: UNKNOWN
-
Optimize the Support of Patients in Pelvic Onco-gynecology Through Adapted Support Care in the Post-cancer Period. AFTERGYN Pilot Phase
NCT05731661 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
NCT02558348 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
NCT00114218 ·Status: COMPLETED ·Phase: PHASE2
-
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT01962948 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT02627443 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
NCT02065687 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers
NCT00247988 ·Status: TERMINATED ·Phase: PHASE2
-
Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer
NCT00102414 ·Status: COMPLETED ·Phase: PHASE3
-
Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients
NCT02028117 ·Status: COMPLETED ·Phase: PHASE1
-
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
NCT00390611 ·Status: COMPLETED ·Phase: PHASE2
-
A Prospective Trial of COXEN Chemotherapy Prediction
NCT01228942 ·Status: WITHDRAWN ·Phase: NA
-
Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer
NCT00214058 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT01283035 ·Status: COMPLETED ·Phase: PHASE2
-
Helping Ovarian Cancer Patients Cope With Their Illness (HOPE)
NCT06666218 ·Status: SUSPENDED ·Phase: NA
-
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
NCT06710288 ·Status: RECRUITING ·Phase: PHASE2
-
Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
NCT00003691 ·Status: COMPLETED ·Phase: PHASE3
-
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00262847 ·Status: COMPLETED ·Phase: PHASE3
-
Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02316834 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
NCT07144254 ·Status: RECRUITING ·Phase: PHASE1